BioNTech and BMS Score in Bispecific Battle with Pumitamig Data

BioNTech and BMS Reveal Promising Phase 2 Pumitamig Data in NSCLC

BioNTech and Bristol Myers Squibb presented positive Phase 2 data for their bispecific antibody pumitamig in combination with chemotherapy for previously untreated advanced non-small cell lung cancer (NSCLC) at the ASCO annual meeting. The ROSETTA Lung-02 trial, involving 40 patients, demonstrated a confirmed objective response rate of 57.1% in non-squamous NSCLC and 68.4% in squamous NSCLC, with a 100% disease control rate at nine months. The safety profile showed Grade 3 treatment-related adverse events in 23.3% of patients, leading to discontinuation in 9.3%. These results are considered comparable to other treatments like ivonescimab, and pivotal Phase 3 trials are actively enrolling.

• The Phase 2 ROSETTA Lung-02 trial showcased compelling efficacy for pumitamig plus chemotherapy in advanced NSCLC. Specifically, patients with non-squamous NSCLC achieved a 57.1% confirmed objective response rate, while those with squamous NSCLC saw a 68.4% ORR. The combination also achieved a 100% disease control rate across the global patient population at nine months, indicating broad disease stabilization.
• The safety data from the ROSETTA Lung-02 trial indicated a manageable profile for pumitamig. Grade 3 treatment-related adverse events (TRAEs) were observed in 23.3% of patients, with treatment discontinuation due to TRAEs occurring in 9.3% of the cohort. These rates suggest that the combination therapy is generally well-tolerated, supporting its continued development.
• Pumitamig, a PD-1/VEGF bispecific antibody, is advancing rapidly, with pivotal Phase 3 trials in NSCLC actively enrolling. Beyond lung cancer, BioNTech and Bristol Myers Squibb are also investigating pumitamig in other challenging indications, including small-cell lung, triple-negative breast, colorectal, and gastric cancers, highlighting its broad therapeutic potential and strategic importance in their oncology pipeline.

Pumitamig's Promising Phase 2 Data in Advanced NSCLC

Recent studies across Non-small cell lung cancer have provided important insights into both established and emerging therapeutic approaches. The data encompasses a range of treatment modalities from targeted therapies to immunotherapy combinations, with studies spanning from Phase 2 trials to comprehensive meta-analyses.

• TROPION-Lung10 (NCT06357533, 2026) - Phase 3 randomized study evaluating datopotamab deruxtecan (6 mg/kg IV Q3W) plus rilvegostomig (750 mg IV Q3W) versus rilvegostomig alone versus pembrolizumab in approximately 675 adults with nonsquamous stage IIIB/C or IV NSCLC with PD-L1 TC ≥50% and no actionable genomic alterations

• ALEX Trial Final Analysis (2025) - Alectinib 600 mg BID versus crizotinib 250 mg BID in 303 treatment-naïve ALK-positive NSCLC patients demonstrated median OS of 81.1 months versus 54.2 months (HR 0.78, 95% CI 0.56-1.08) with median duration of response 42.3 months versus 11.1 months (HR 0.41, 95% CI 0.30-0.56)

• RATIONALE-307 4-year Follow-up (2026) - Tislelizumab plus chemotherapy in treatment-naive advanced squamous NSCLC showed 4-year OS rates of 32.2% (tislelizumab plus paclitaxel/carboplatin), 26.0% (tislelizumab plus nab-paclitaxel/carboplatin), versus 19.2% (chemotherapy alone) with median OS of 26.1, 23.3, and 19.4 months respectively

• Tislelizumab Meta-analysis (2026) - Comprehensive analysis of randomized controlled trials demonstrated 41% reduction in disease progression/death risk (HR 0.59, 95% CI 0.52-0.67), 35% reduction in overall survival risk (HR 0.65, 95% CI 0.59-0.73), with improved median PFS by 1.77 months and manageable safety profile

• CJLSG1901 Subgroup Analysis (2026) - Pembrolizumab plus pemetrexed in 49 older patients with metastatic non-squamous NSCLC achieved overall ORR 36.7%, median PFS 7.6 months, and median OS 19.4 months, with PD-L1 1%-49% group showing superior outcomes (ORR 46.4%, median PFS 7.8 months) compared to PD-L1 <1% group (ORR 23.8%, median PFS 4.4 months)

• F1NE TUNE Study (2025) - Atezolizumab with carboplatin plus nab-paclitaxel in 52 chemotherapy-naïve patients with TTF-1-negative advanced nonsquamous NSCLC achieved median PFS 4.9 months (80% CI 4.3-5.9), median OS 13.2 months (95% CI 10.3-27.2), and response rate 56.9% (95% CI 43.3-69.5%) but did not meet the primary endpoint threshold

Unpacking the ROSETTA Lung-02 Trial Design

Recent NSCLC trials demonstrate a shift toward biomarker-driven patient selection and combination therapy strategies, with studies spanning from early-phase dose-finding to real-world evidence generation. The trial landscape encompasses targeted therapies for specific mutations (EGFR, ALK, MET, HER2), immunotherapy approaches, and novel combination regimens across diverse patient populations.

Pumitamig's Strong Phase 2 Data Reshapes First-Line NSCLC Outlook

The recent presentation of positive Phase 2 data for pumitamig, a bispecific antibody, in combination with chemotherapy for previously untreated advanced non-small cell lung cancer (NSCLC) signals a potentially transformative moment for patients facing this aggressive disease. Bispecific antibodies represent a rapidly evolving class of therapeutics, with agents like amivantamab, mosunetuzumab, and elranatamab already demonstrating significant efficacy in various cancers by engaging immune cells or targeting multiple oncogenic pathways. Pumitamig's impressive objective response rates of 57.1% in non-squamous and 68.4% in squamous NSCLC, alongside a remarkable 100% disease control rate at nine months, suggest a highly active regimen for initial therapy. This combination strategy is particularly compelling, as research indicates that chemotherapy can synergistically enhance the immune response mediated by bispecific antibodies, potentially leading to deeper and more sustained tumor control.

However, the path forward is not without its considerations. While the Phase 2 safety profile, with 23.3% Grade 3 treatment-related adverse events, appears manageable, the experience with other bispecific antibodies suggests that immune-related toxicities can become more pronounced or complex in larger patient cohorts. Careful monitoring and proactive management strategies will be crucial to ensure patient safety and treatment adherence in pivotal Phase 3 trials. Furthermore, the NSCLC market is intensely competitive, with several bispecific antibodies, including ivonescimab, already vying for market share. Pumitamig will need to clearly demonstrate a superior or uniquely differentiated efficacy and safety profile to carve out a significant position. Ultimately, the long-term durability of response and overall survival data from the ongoing Phase 3 studies will be the definitive measure of pumitamig's potential to redefine the first-line treatment landscape for advanced NSCLC, offering a new, highly effective immunotherapeutic backbone.